Amy M Lin

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Prostate cancer update: 2007
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Curr Opin Oncol 20:294-9. 2008
  2. doi request reprint Management of hormone refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Curr Opin Support Palliat Care 1:187-91. 2007
  3. ncbi request reprint Intermittent chemotherapy for metastatic hormone refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Crit Rev Oncol Hematol 61:243-54. 2007
  4. ncbi request reprint Prostate cancer update: 2006
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Curr Opin Oncol 19:229-33. 2007
  5. ncbi request reprint A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 5:323-8. 2007
  6. ncbi request reprint A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
    Amy M Lin
    University of California San Francisco, San Francisco, CA 94115, USA
    BJU Int 98:763-9. 2006
  7. doi request reprint Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
    Terence W Friedlander
    Urologic Oncology Program, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 30:408-14. 2012
  8. doi request reprint A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    Terence W Friedlander
    Genitourinary Medical Oncology Program, Biostatistics and Computational Biology Core, Helen Diller Family Comprehensive Cancer Center, Department of Bioengineering and Therapeutic Sciences, Box 1711, 1600 Divisadaro Street, University of California, San Francisco, San Francisco, CA 94115 1711, USA
    Oncol Rep 27:3-9. 2012
  9. doi request reprint A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
    Andrea L Harzstark
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1711, USA
    Cancer 117:4194-200. 2011
  10. doi request reprint Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF
    Lawrence Fong
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Res 69:609-15. 2009

Detail Information

Publications14

  1. doi request reprint Prostate cancer update: 2007
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Curr Opin Oncol 20:294-9. 2008
    ..The present review highlights the year's most important developments in the risk assessment, diagnosis, and treatment of prostate cancer...
  2. doi request reprint Management of hormone refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Curr Opin Support Palliat Care 1:187-91. 2007
    ..This review highlights the most interesting developments and outstanding issues surrounding the management of hormone-refractory prostate cancer published in the medical literature during the past year...
  3. ncbi request reprint Intermittent chemotherapy for metastatic hormone refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Crit Rev Oncol Hematol 61:243-54. 2007
    ....
  4. ncbi request reprint Prostate cancer update: 2006
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Curr Opin Oncol 19:229-33. 2007
    ..This review highlights the most important developments in the diagnosis, prevention, and treatment of prostate cancer published in the medical literature over the past year...
  5. ncbi request reprint A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 5:323-8. 2007
    ..Imatinib inhibits the platelet-derived growth factor receptor that is expressed in prostate cancer and is synergistic with taxanes in preclinical prostate cancer models...
  6. ncbi request reprint A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
    Amy M Lin
    University of California San Francisco, San Francisco, CA 94115, USA
    BJU Int 98:763-9. 2006
    ..East Hanover, NJ, USA), as measured by prostate-specific antigen (PSA) kinetics in men with biochemical relapse of prostate cancer after definitive local therapy...
  7. doi request reprint Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
    Terence W Friedlander
    Urologic Oncology Program, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 30:408-14. 2012
    ..In this study, the efficacy of depot octreotide acetate was prospectively evaluated in patients with CRPC...
  8. doi request reprint A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    Terence W Friedlander
    Genitourinary Medical Oncology Program, Biostatistics and Computational Biology Core, Helen Diller Family Comprehensive Cancer Center, Department of Bioengineering and Therapeutic Sciences, Box 1711, 1600 Divisadaro Street, University of California, San Francisco, San Francisco, CA 94115 1711, USA
    Oncol Rep 27:3-9. 2012
    ..NDGA therapy lengthens median PSADT but does not induce significant PSA declines. Further study may require a placebo-control to determine if changes in PSADT are drug related...
  9. doi request reprint A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
    Andrea L Harzstark
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1711, USA
    Cancer 117:4194-200. 2011
    ....
  10. doi request reprint Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF
    Lawrence Fong
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Res 69:609-15. 2009
    ....
  11. ncbi request reprint Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale
    Charles J Ryan
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 24:250-3. 2006
    ..This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies...
  12. ncbi request reprint Clinical trials in patients with biochemically relapsed prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    BJU Int 97:905-10. 2006
    ..Finally there are two papers from Australia describing the use of positron emission tomography in renal cancer and in prostate cancer...
  13. pmc Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences
    Henry Chow
    Department of Radiology, University of California San Francisco, San Francisco, CA 94143 0628, USA
    J Comput Assist Tomogr 35:86-90. 2011
    ..To describe the computed tomographic (CT) appearances and clinical consequences of tumor fistulization as a complication of targeted therapy for cancer...
  14. ncbi request reprint Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
    Amy M Lin
    Department of Medicine, University of California, San Francisco, San Francisco, CA 94115, USA
    Urol Oncol 24:434-41. 2006
    ..This review will summarize the prostate cancer clinical trials using APC8015 and discuss the potential future role of APC8015 in prostate cancer treatment...